Upstream / Downstream


Explore pathways related to this product.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of the holidays. We will reopen on Monday, December 28th.

Thank you for your patience.

To Purchase # 8917SC

8917SC 50 µg (With Carrier) $179.00
8917SF 50 µg (Carrier Free) $179.00
8917LC 250 µg (With Carrier) $529.00
8917LF 250 µg (Carrier Free) $529.00


Find answers on our FAQs page.


Visit PhosphoSitePlus®

PTM information and tools available.


Source / Purification

Recombinant human IGF-I (hIGF-I) Gly49-Ala118 (Accession #P01343) was produced in E. coli at Cell Signaling Technology.

Product Description


>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIGF-I. All lots are greater than 98% pure.

Molecular Formula:

Recombinant hIGF-I has a Met on the amino terminus and has a calculated MW of 7,785. DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. The expected amino-terminal MGPET of recombinant hIGF-I was verified by amino acid sequencing.


The bioactivity of recombinant hIGF-I was determined in a cell proliferation assay using primary human dermal fibroblasts. The ED50 of each lot is between 2-8 ng/ml.


Less than 0.01 ng endotoxin/1 μg hIGF-I.

Product Usage Information


With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hIGF-I. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.

Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

Most circulating endocrine acting IGF-I is produced by hepatocytes, and paracrine or autocrine acting IGF-I is produced by defined cell types within specific tissues (1,2). Many neoplastic cells produce IGF-I, which regulates a number of cellular processes including energy metabolism, proliferation, and cell survival (3,4). IGF-I activity is regulated by one or more of the six extracellular IGF-binding proteins (IGFBPs). IGFBPs bind to IGF-I and most inhibit IGF-I binding to IGF-I receptor (IGFIR) (1,2). Some IGFBPs may increase cell responses to IGF-I. Binding of IGF-I to IGFIR activates the Akt, JNK, and Erk pathways (2). IGF-I and IGFIR are frequently expressed by cancer cells and may contribute to the proliferation and viability of a number of cancer types (1,2).

1.  Pollak, M. (2008) Nat Rev Cancer 8, 915-28.

2.  Chitnis, M.M. et al. (2008) Clin Cancer Res 14, 6364-70.

3.  Karey, K.P. and Sirbasku, D.A. (1988) Cancer Res 48, 4083-92.

4.  Small, T.W. and Pickering, J.G. (2009) J Biol Chem 284, 24684-95.

Entrez-Gene Id 3479
Swiss-Prot Acc. P05019

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Human Insulin-like Growth Factor I (hIGF-I)